Kaletra
Sponsors
Pfizer, GlaxoSmithKline, Therapeutic Concepts, University of North Carolina, Chapel Hill, Ines Perez
Conditions
HIVHIV InfectionHIV InfectionsHIV-infected ChildrenInfection, Human Immunodeficiency VirusPediatric AIDSPregnancy
Phase 1
Phase 2
Four-Drug Combination Treatment in Hiv-Infected Subjects Failing Therapy With Antiretroviral Regimens
CompletedNCT00052117
Start: 2003-01-31End: 2005-05-31Target: 300Updated: 2007-10-10
Study of the 48-Week Virologic and Immunologic Response to Lopinavir/Ritonavir (Kaletra) in HIV Positive Adult Patients
CompletedNCT00116636
Start: 2005-06-30End: 2007-12-31Target: 40Updated: 2017-05-01
Early Infant HIV Treatment in Botswana
Active, not recruitingNCT02369406
Start: 2015-05-04End: 2029-06-30Updated: 2026-02-23
Phase 3
KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks
CompletedNCT00085943
Start: 2004-05-31Target: 866Updated: 2011-05-16
Pediatric Study for Appropriate Dose of Ritonavir Boosted Lopinavir in Thai HIV-infected Children (PEARL)
CompletedNCT01307124
Start: 2011-03-31End: 2013-04-30Updated: 2015-03-25